Cite
HARVARD Citation
Berstein, G. et al. (2021). A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis. Clinical and experimental dermatology. pp. 122-129. [Online].